VADDI KRISHNA (President, CEO) purchased 3.6% of their position (5K shares) of PRELUDE THERAPEUTICS INC on the open market
Open‑market purchase worth $6.0K — a small addition. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 1/3/2025ACC: 0001562180-25-000031
DirectorOfficer· President, CEO
Since Sep 2020
+5K
Net shares
Net buyer
$6.0K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
5K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+5K
Price / share
$1.21
Trade value
$6.04K
% of position
3.6%
12/31/2024
137.55K→142.55K
Total
Net shares
+5K
Net value
$6.04K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 12/31/2024 | P · Purchase | +5K | $1.21 | $6.04K | 3.6% | 137.55K | 142.55K |
| Total | +5K | $6.04K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)4
Common Stock
IndirectShares owned551.77K
Common Stock
DirectShares owned1.17M
Common Stock
IndirectShares owned423.65K
Common Stock
IndirectShares owned551.78K
Total
1.17M direct·1.53M indirect2.69M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 551.77K | Indirect |
| Common Stock | 1.17M | Direct |
| Common Stock | 423.65K | Indirect |
| Common Stock | 551.78K | Indirect |
| Total | 2.69M | 1.17M direct·1.53M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported